Eli Lilly | LLY - Trade Creditors


Eli Lilly reported $5.79B in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Abbott USD 4.68B 439M Mar/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
Baxter International USD 1.02B 10M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Drreddys Laboratories INR 22.36B 21.91B Mar/2026
Eli Lilly USD 5.79B 319M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
J&J USD 9.32B 94M Sep/2026
Medtronic USD 2.7B 51M Jun/2026
Merck USD 3.83B 36M Jun/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Novartis USD 4.32B 134M Mar/2026
Novo Nordisk DKK 14.59B 212M Jun/2026
Perrigo USD 400.4M 34.4M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
Phibro Animal Health USD 127.31M 2.33M Jun/2026
Prestige Brands USD 36.85M 14.06M Jun/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 23.6B 888M Jun/2026
Sanofi EUR 22.71B 219M Mar/2026
United Therapeutics USD 497.8M 500K Jun/2026
Zoetis USD 452M 55M Jun/2026